Fort Washington Investment Advisors Inc. OH Acquires New Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Fort Washington Investment Advisors Inc. OH bought a new stake in Charles River Laboratories International, Inc. (NYSE:CRL) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 900 shares of the medical research company’s stock, valued at approximately $213,000.

Several other large investors also recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its holdings in shares of Charles River Laboratories International by 0.5% during the 3rd quarter. Vanguard Group Inc. now owns 5,953,860 shares of the medical research company’s stock worth $1,166,837,000 after buying an additional 29,482 shares during the period. BlackRock Inc. boosted its holdings in Charles River Laboratories International by 8.6% during the second quarter. BlackRock Inc. now owns 5,198,037 shares of the medical research company’s stock valued at $1,092,887,000 after acquiring an additional 411,153 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in Charles River Laboratories International by 35.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 2,506,293 shares of the medical research company’s stock valued at $505,821,000 after acquiring an additional 653,790 shares during the period. State Street Corp grew its position in shares of Charles River Laboratories International by 1.8% in the second quarter. State Street Corp now owns 2,091,017 shares of the medical research company’s stock valued at $439,636,000 after purchasing an additional 37,816 shares during the last quarter. Finally, Kayne Anderson Rudnick Investment Management LLC increased its stake in shares of Charles River Laboratories International by 3.9% in the third quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,746,101 shares of the medical research company’s stock worth $342,201,000 after purchasing an additional 64,981 shares during the period. 98.91% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

CRL has been the subject of several research reports. Guggenheim cut shares of Charles River Laboratories International from a “buy” rating to a “neutral” rating in a research note on Thursday, February 15th. JPMorgan Chase & Co. lifted their target price on Charles River Laboratories International from $270.00 to $280.00 and gave the company an “overweight” rating in a research note on Thursday, February 15th. TheStreet raised Charles River Laboratories International from a “c+” rating to a “b-” rating in a research note on Friday, March 1st. Evercore ISI increased their price target on Charles River Laboratories International from $260.00 to $265.00 and gave the stock an “outperform” rating in a report on Thursday, February 15th. Finally, Argus boosted their price target on Charles River Laboratories International from $240.00 to $290.00 and gave the company a “buy” rating in a report on Monday, March 18th. Six research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $249.64.

Insider Transactions at Charles River Laboratories International

In other news, EVP Victoria L. Creamer sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $253.70, for a total transaction of $1,268,500.00. Following the completion of the sale, the executive vice president now owns 13,550 shares of the company’s stock, valued at approximately $3,437,635. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, EVP Shannon M. Parisotto sold 5,882 shares of the business’s stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $241.20, for a total value of $1,418,738.40. Following the sale, the executive vice president now owns 2,596 shares of the company’s stock, valued at $626,155.20. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Victoria L. Creamer sold 5,000 shares of the stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $253.70, for a total value of $1,268,500.00. Following the completion of the sale, the executive vice president now directly owns 13,550 shares of the company’s stock, valued at approximately $3,437,635. The disclosure for this sale can be found here. In the last three months, insiders have sold 14,932 shares of company stock valued at $3,693,663. 1.30% of the stock is owned by corporate insiders.

Charles River Laboratories International Stock Performance

NYSE CRL opened at $269.37 on Thursday. Charles River Laboratories International, Inc. has a 52-week low of $161.65 and a 52-week high of $275.00. The stock has a market cap of $13.82 billion, a PE ratio of 29.25, a P/E/G ratio of 2.08 and a beta of 1.39. The firm has a 50-day moving average of $242.91 and a 200-day moving average of $215.59. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.16 and a current ratio of 1.52.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Wednesday, February 14th. The medical research company reported $2.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.39 by $0.07. Charles River Laboratories International had a net margin of 11.49% and a return on equity of 16.53%. The company had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $991.25 million. During the same quarter in the previous year, the business posted $2.98 earnings per share. Charles River Laboratories International’s quarterly revenue was down 7.9% on a year-over-year basis. On average, sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 11.01 EPS for the current year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).